[Malignant Lymphoma of the Skin: Update on Diagnostics and Therapy of Primary Cutaneous B-cell Lymphoma]

Overview

Journal Hautarzt

Specialty Dermatology

Date 2011 Dec 14

PMID 22160228

Authors

C Hallermann

C Niermann

M Fluck

A-R Fischedick

H-J Schulze

Affiliations

Soon will be listed here.

Abstract

The diagnosis of primary cutaneous B-cell lymphoma is made based principally on the results of histological investigations and staging. For an exact staging abdominal sonography and chest X-ray examinations and for appropriate clinical symptoms special investigations as well as radiological imaging procedures including PET are indicated in addition to conventional laboratory investigations. For therapy rituximab is normally administered as monotherapy in order to avoid over therapy of indolent lymphoma. Further options are radiotherapy and new approaches with electrochemotherapy as well as pegylated doxorubicin.

References

Verma S, Frambach G, Seilstad K, Nuovo G, Porcu P, Magro C . Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol. 2005; 32(7):474-83. DOI: 10.1111/j.0303-6987.2005.00363.x. View

Streubel B, Scheucher B, Valencak J, Huber D, Petzelbauer P, Trautinger F . Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol. 2006; 30(4):529-36. DOI: 10.1097/00000478-200604000-00015. View

Wahie S, Dayala S, Husain A, Summerfield G, Hervey V, Langtry J . Cutaneous features of intravascular lymphoma. Clin Exp Dermatol. 2011; 36(3):288-91. DOI: 10.1111/j.1365-2230.2010.03934.x. View

Neelis K, Schimmel E, Vermeer M, Senff N, Willemze R, Noordijk E . Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2008; 74(1):154-8. DOI: 10.1016/j.ijrobp.2008.06.1918. View

Niermann C, Schulze H, Hallermann C . [The history of lymphoma classifications with special consideration of cutaneous lymphomas]. Hautarzt. 2008; 59(5):394-9. DOI: 10.1007/s00105-008-1527-x. View

Wobser M, Kneitz H, Brocker E, Becker J . Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges. J Dtsch Dermatol Ges. 2010; 9(3):204-11. DOI: 10.1111/j.1610-0387.2010.07578.x. View

Garcia C, Florez A, Pardavila R, Garcia-Cruz A, Amador L, Alvarez M . Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy. Eur J Dermatol. 2009; 19(4):394-5. DOI: 10.1684/ejd.2009.0688. View

Spugnini E, Citro G, Mellone P, Dotsinsky I, Mudrov N, Baldi A . Electrochemotherapy for localized lymphoma: a preliminary study in companion animals. J Exp Clin Cancer Res. 2007; 26(3):343-6. View

Hallermann C, Kaune K, Gesk S, Martin-Subero J, Gunawan B, Griesinger F . Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol. 2004; 123(1):213-9. DOI: 10.1111/j.0022-202X.2004.22720.x. View

10.

Grange F, Maubec E, Bagot M, Beylot-Barry M, Joly P, Dalle S . Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol. 2009; 145(3):329-30. DOI: 10.1001/archdermatol.2009.23. View

11.

Grange F, Petrella T, Beylot-Barry M, Joly P, DIncan M, Delaunay M . Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004; 103(10):3662-8. DOI: 10.1182/blood-2003-08-2726. View

12.

Giannotti B, Santucci M . Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity. Arch Dermatol. 1993; 129(3):353-5. View

13.

Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A . Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol. 2009; 82(3):184-93. DOI: 10.1111/j.1600-0609.2008.01197.x. View

14.

Hallermann C, Niermann C, Fischer R, Schulze H . Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. Acta Derm Venereol. 2011; 91(5):521-5. DOI: 10.2340/00015555-1112. View

15.

Vermeer M, Geelen F, van Haselen C, van Voorst Vader P, Geerts M, van Vloten W . Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol. 1996; 132(11):1304-8. View

16.

Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L . Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005; 106(7):2491-7. DOI: 10.1182/blood-2005-03-1175. View

17.

Senff N, Hoefnagel J, Neelis K, Vermeer M, Noordijk E, Willemze R . Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol. 2007; 143(12):1520-6. DOI: 10.1001/archderm.143.12.1520. View

18.

Fenot M, Quereux G, Brocard A, Renaut J, Dreno B . Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol. 2010; 20(6):753-7. DOI: 10.1684/ejd.2010.1102. View

19.

Morales A, Advani R, Horwitz S, Riaz N, Reddy S, Hoppe R . Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008; 59(6):953-7. DOI: 10.1016/j.jaad.2008.08.005. View

20.

Kim B, Surti U, Pandya A, Cohen J, Rabkin M, Swerdlow S . Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas. Am J Surg Pathol. 2004; 29(1):69-82. DOI: 10.1097/01.pas.0000146015.22624.c7. View